FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to oncology, and can be used for tumour cells growth inhibition. That is ensured by administering an anticancer agent containing (SP-4-3)-(CIS-amindihlorine-[2-methylpyridine] platinum (II) (ZD0473) to patient and another anticancer agent selected from group consisting of taxan, camptothecin, gemcitabine, capecitabine, 5-fluorouracil, vinorelbine, topotecan, anthracycline, irinotecan, etoposide, vinblastine, Pemetrexed, cyclophosphamide, ifosfamide and methotrexate. Components of drug can be introduced simultaneously or separately in series.
EFFECT: group of inventions provides both overcoming of drug resistance and malignant tumours treatment efficiency.
24 cl
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED CHEMOTHERAPY | 2001 |
|
RU2284818C2 |
| COMBINED CHEMOTHERAPY | 2006 |
|
RU2429838C2 |
| METHOD FOR REDUCING MULTI-DRUG RESISTANCE WITH USING INOSITOL TRIPYROPHOSPHATE | 2010 |
|
RU2563127C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
| COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
| COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
| METHODS AND COMPOSITIONS FOR TREATING CANCER | 2009 |
|
RU2508116C2 |
| TREATING LUNG CANCER BY COMBINATION OF ANTI-PD-1 AND OTHER ANTI-CANCER AGENTS | 2015 |
|
RU2695332C2 |
| COMBINED APPLICATION OF ECTEINASCIDIN-743 AND PLATINUM-CONTAINING ANTI-TUMOUR COMPOUNDS | 2004 |
|
RU2391101C2 |
